Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FuFei HuaZhuo TongLuo Granule
- Development stage
- Unknown
- Lead developer
- Hangzhou First People's Hospital
- Administration
- Oral
01
Overview
FuFei HuaZhuo TongLuo Granule (also known as Fufei Huazhuo Tongluo Formula) is an investigational traditional Chinese medicine (TCM) herbal formulation developed by Hangzhou First People's Hospital. It is currently being evaluated in clinical trials for the treatment of anti-synthetase syndrome-associated interstitial lung disease (ASS-ILD). The granule is administered orally in combination with standardized Western medicine to evaluate its potential for glucocorticoid-sparing efficacy, delaying lung function decline, reducing infection risk, and improving traditional Chinese medicine syndrome scores.
- Other names
- Fufei Huazhuo Tongluo FormulaFufei Huazhuo Tongluo Granule
Beyond the preview
Go deeper on FuFei HuaZhuo TongLuo Granule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FuFei HuaZhuo TongLuo Granule.